Long-term survivors of glioblastoma: Statistical aberration or important unrecognized molecular subtype?

Cancer Journal

Volumn 9, Issue 3, 2003, Pages 214-221

  Senger, Donna ^a   Cairncross, J Gregory ^a   Forsyth, Peter A J ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Brain tumor; Glioblastoma multiforme; Long term survivor; Molecular markers

Indexed keywords

BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CHROMOSOME ABERRATION; CLINICAL FEATURE; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DNA MICROARRAY; GENE MUTATION; GLIOBLASTOMA; HISTOLOGY; HUMAN; MEDICAL RESEARCH; MULTIMODALITY CANCER THERAPY; OUTCOMES RESEARCH; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME; AGE; EPIDEMIOLOGY; KARNOFSKY PERFORMANCE STATUS; METABOLISM; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; SURVIVOR; TUMOR SUPPRESSOR GENE;

TUMOR MARKER;

AGE FACTORS; BIAS (EPIDEMIOLOGY); BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GENES, P53; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; SURVIVORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0642366703     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200305000-00009     Document Type: Review

References (67)

1. Chandler KL, Prados MD, Malec M et al. Long-term survival in patients with glioblastoma multiforme. Neurosurgery 1993;32:716-720.
2. Salvati M, Cervoni L, Artico M et al. Long-term survival in patients with supratentorial glioblastoma. J Neurooncol 1998;36:61-64.
3. Puzzilli F, Ruggeri A, Mastronardi L et al. Long-term survival in cerebral glioblastoma: case report and critical review of the literature. Tumori 1998;84:69-74.
4. Davis FG, Freels S, Grutsch J et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998;88:1-10.
5. Scott JN, Rewcastle NB, Brasher PM et al. Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci 1998;3:197-201.
6. Bruner JM, Inouye L, Fuller GN et al. Diagnosis discrepancies and their clinical impact in a neuropathology referral practice. Cancer 1997;79:796-803.
7. Salford L, Brun A, Nirfalk S. Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 1988;69:506-509.
8. Morita M, Rosenblum MK, Bilsky MH et al. Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neurooncol 1996;27:259-266.
9. Scott JN, Rewcastle NB, Brasher PM et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999:46:183-188.
10. Ullén H, Mattsson B, Collins VP. Long-term survival after malignant glioma: a clinical and histopathological study on the accuracy of the diagnosis in a population-based cancer registry. Acta Oncol 1990;29:875-878.
11. Balmaceda C, Goldman J, Fetell MR. Long-term survival in malignant astrocytomas re-evaluated: are they really oligodendrogliomas? [abstract] Neurology 1996;46:A451.
12. Cairncross JB, MacDonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;4:360-364.
13. MacDonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573-574.
14. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
15. Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-845.
16. Ino Y, Zlatescu MC, Sasaki H et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000;6:1080-1081.
17. Burger PC, Scheithauer BW, Lee RL et al. An interdisciplinary approach to avoid the overtreatment of patients with central nervous system lesions. Cancer 1997;80:2040-2046.
18. Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. Cancer 1979;44:1839-1852.
19. Forsyth PA, Shaw E, Scheithauer B et al. 51 Cases of supratentorial pilocytic astrocytoma: a clinicopathologic, prognostic, and flow-cytometric study. Cancer 1993;72:1335-1342.
20. Elvidge AR, Barone BM. Long-term postoperative survival in two cases of glioblastoma multiforme. J Neurosurg 1965;22:382-386.
21. Müller H, Brock, M, Ernst H. Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas. Clin Neurol Neurosurg 1985;87:167-171.
22. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 1990;28:818-822.
23. Vertosick FT, Selker RG. Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 1992;38:359-363.
24. Salcman M, Scholtz H, Kaplan RS, Kulik S. Long-term survival in patients with malignant astrocytoma. Neurosurgery 1994;34:213-220.
25. Olivera C, Bartley M, Ferrall S, Phuphanich S. Long-term malignant glioma survivors over ten years: prognostic factors [abstract]. ASCO Proc 1997;16:407a.
26. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-1329.
27. Fine HA, Dear KBG, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-2597.
28. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 1993;85:704-710.
29. Stupp R, Dietrich P-Y, Kraljevic SO et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Neurooncol 2002;20:1375-1382.
30. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms: a retrospective study of clinical parameters, therapy and outcome. J Neurosurg 1993;78:767-775.
31. Kreth FW, Warnke PC, Scheremet R et al. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993;78:762-766.
32. Berger MS, Deliganis AV, Dobbins J et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 194;74:1784-1791.
33. Rostomily RC, Spence AM, Duong D et al. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35:378-388.
34. Kowalczuk A, Macdonald RL, Amidei C et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1998;43:398-399.
35. Wisoff JH, Boyett JM, Berger MS et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 1999;90:1147-1148.
36. Rasheed ABK, Wiltshire RN, Bigner SH et al. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999;11:162-175.
37. Hu J, Pang JC, Tong CY et al. High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumors. Br J Cancer 2002;2:218-224.
38. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
39. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1- and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-645.
40. Schmidt MC, Antweiler S, Urban N et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-328.
41. Von Deimling A, von Ammon K, Schoenfeld D et al. 1993 Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;1:19-26.
42. Watanabe K, Tachibana O, Sata K et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-223.
43. Hayashi Y, Ueki K, Waha A et al. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997;7:871-875.
44. Burton EC, Lamborn KR, Forsyth P et al. Aberrant p53, mdm2 and proliferation differ in glioblastomas for long-term compared with typical survivors. Clin Cancer Res 2002;1:180-187.
45. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
46. Chakravarti A, Delaney MA, Noll E et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001;8:2387-2395.
47. Simmons ML, Lamborn KR, Takahashi M et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor and survival in glioblastoma patients. Cancer Res 2001;61:1122-1128.
48. Biernat W, Kleihues P, Yonekawa Y et al. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 1997;56:180-185.
49. Rainov NG, Dobberstein KU, Bahn H et al. Prognostic factors in malignant gliomas: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J. Neurooncol 1997:35;13-28.
50. Reifenberger G, Liu L, Ichimura K et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-2739.
51. Kraus JA, Wenghoefer M, Schmidt MC et al. Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J. Neurol 2000;247:455-460.
52. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human gliomas. Cancer Res 2002;62:4364-4368.
53. Rickman DS, Bobek MP, Misek DE et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001;61:6885-6891.
54. Sallinen S, Sallinen PK, Haapasalo HK et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000;60:6617-6622.
55. Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture microdissection. Science 1996;274:998-1001.
56. Bonner RF, Emmert-Buck M, Cole K et al. Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481-1483.
57. Schrock E, du Manoir S, Veldman T et al. Multicolor spectral karyotyping of human chromosomes. Science 1996;273:494-497.
58. Speicher MR, Ballard GS, Ward DC. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 1996;12:368-375.
59. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000;290:1760-1763.
60. Kallioniemi OP, Kallioniemi A, Piper J et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994;10:231-243.
61. Nachman MW. Single nucleotide polymorphisms and recombination rate in humans. Trends Genet 2001;17:481-485.
62. Schena M, Shalon D, Davis RW et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:470.
63. Velculescu VE, Zhang L, Vogelstein B et al. Serial analysis of gene expression. Science 1995;270;484-487.
64. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;7:844-847.
65. Frantz GD, Pham TQ, Peale FV et al. Detection of novel gene expression in paraffin-embedded tissues by isotopic in situ hybridization in tissue microarrays. J Pathol 2001;195:87-96.
66. Gygi SP, Rist B, Gerber SA et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-999.
67. Burton EC, Lamborn KR, Feuerstein BG et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002;62:6205-6210.